Published in J Biol Chem on January 29, 1999
Photodynamic therapy of cancer: an update. CA Cancer J Clin (2011) 6.08
Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer (2006) 3.93
Mechanisms in photodynamic therapy: part two-cellular signaling, cell metabolism and modes of cell death. Photodiagnosis Photodyn Ther (2005) 1.52
Endoplasmic reticulum and Golgi apparatus are the preferential sites of Foscan localisation in cultured tumour cells. Br J Cancer (2003) 0.98
Immunogenic cell death: can it be exploited in PhotoDynamic Therapy for cancer? Biomed Res Int (2012) 0.87
Photodynamic Synergistic Effect of Pheophorbide a and Doxorubicin in Combined Treatment against Tumoral Cells. Cancers (Basel) (2017) 0.75
Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science (2001) 7.66
RelB, a new Rel family transcription activator that can interact with p50-NF-kappa B. Mol Cell Biol (1992) 4.03
Specific interaction of cellular factors with the B enhancer of polyoma virus. EMBO J (1985) 3.23
The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes. Mol Cell Biol (1994) 3.16
IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell (2001) 3.10
Two different factors bind to the alpha-domain of the polyoma virus enhancer, one of which also interacts with the SV40 and c-fos enhancers. EMBO J (1987) 3.09
The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-kappa B-mediated inhibition. Nature (1992) 2.95
Expression of protein encoded by varicella-zoster virus open reading frame 63 in latently infected human ganglionic neurons. Proc Natl Acad Sci U S A (1996) 2.71
TNF stimulates expression of mouse MHC class I genes by inducing an NF kappa B-like enhancer binding activity which displaces constitutive factors. EMBO J (1989) 2.65
Induction of a factor that binds to the polyoma virus A enhancer on differentiation of embryonal carcinoma cells. Nature (1987) 2.65
Varicella-zoster virus gene 63 encodes an immediate-early protein that is abundantly expressed during latency. J Virol (1995) 2.58
Quality of life in persons with human immunodeficiency virus infection: measurement by the Medical Outcomes Study instrument. Ann Intern Med (1992) 2.40
Activation of the polyomavirus enhancer by a murine activator protein 1 (AP1) homolog and two contiguous proteins. Proc Natl Acad Sci U S A (1988) 2.24
The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc Natl Acad Sci U S A (1993) 2.01
DNA sequence of the carA gene and the control region of carAB: tandem promoters, respectively controlled by arginine and the pyrimidines, regulate the synthesis of carbamoyl-phosphate synthetase in Escherichia coli K-12. Proc Natl Acad Sci U S A (1984) 1.81
Differences in access to zidovudine (AZT) among symptomatic HIV-infected persons. J Gen Intern Med (1991) 1.80
IS3 can function as a mobile promoter in E. coli. Nucleic Acids Res (1982) 1.75
Characterization of regulatory functions of the varicella-zoster virus gene 63-encoded protein. J Virol (1992) 1.68
The oncoprotein Bcl-3 can facilitate NF-kappa B-mediated transactivation by removing inhibiting p50 homodimers from select kappa B sites. EMBO J (1993) 1.61
The regulatory region of the divergent argECBH operon in Escherichia coli K-12. Nucleic Acids Res (1982) 1.60
The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. Clin Genet (2010) 1.58
Reactive oxygen intermediate-dependent NF-kappaB activation by interleukin-1beta requires 5-lipoxygenase or NADPH oxidase activity. Mol Cell Biol (1999) 1.57
PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress. Cell Death Differ (2012) 1.57
Variation in health service use among HIV-infected patients. Med Care (1992) 1.56
Molecular basis for modulated regulation of gene expression in the arginine regulon of Escherichia coli K-12. Nucleic Acids Res (1983) 1.49
Homologous control sites and DNA transcription starts in the related argF and argI genes of Escherichia coli K12. EMBO J (1982) 1.43
Combined suicide and cytokine gene therapy for peritoneal carcinomatosis. Gut (2000) 1.39
NF- kappa B2/p100 induces Bcl-2 expression. Leukemia (2003) 1.39
Evolutionary divergence of genes for ornithine and aspartate carbamoyl-transferases--complete sequence and mode of regulation of the Escherichia coli argF gene; comparison of argF with argI and pyrB. Nucleic Acids Res (1984) 1.37
Crucial role of the amino-terminal tyrosine residue 42 and the carboxyl-terminal PEST domain of I kappa B alpha in NF-kappa B activation by an oxidative stress. J Immunol (2000) 1.33
Intracellular transport of the glycoproteins gE and gI of the varicella-zoster virus. gE accelerates the maturation of gI and determines its accumulation in the trans-Golgi network. J Biol Chem (1998) 1.31
Characterization of the regulatory functions of varicella-zoster virus open reading frame 4 gene product. J Virol (1993) 1.30
Efficient formation of a crosslinkable HMT monoadduct at the Kpn I recognition site. Photochem Photobiol (1984) 1.30
Highly-expressed p100/p52 (NFKB2) sequesters other NF-kappa B-related proteins in the cytoplasm of human breast cancer cells. Oncogene (1995) 1.29
Protein-binding elements in the promoter region of the mouse p53 gene. Oncogene (1990) 1.27
Vimentin expression in cervical carcinomas: association with invasive and migratory potential. J Pathol (1996) 1.27
Oxidative stress interference with the nuclear factor-kappa B activation pathways. Biochem Pharmacol (2000) 1.25
An in vivo model of varicella-zoster virus latent infection of dorsal root ganglia. J Neurosci Res (1990) 1.25
MDM2: life without p53. Trends Genet (2001) 1.22
Communication of preferences for care among human immunodeficiency virus-infected patients. Barriers to informed decisions? Arch Fam Med (1997) 1.21
Molecular analysis of the interaction between an enhancer binding factor and its DNA target. Nucleic Acids Res (1986) 1.19
Regulation of NF-kappaB activity by I kappaB-related proteins in adenocarcinoma cells. Oncogene (1999) 1.18
Varicella-zoster virus induces apoptosis in cell culture. J Gen Virol (1995) 1.15
The ATM protein is required for sustained activation of NF-kappaB following DNA damage. Oncogene (1999) 1.14
Mutational analysis of the p50 subunit of NF-kappa B and inhibition of NF-kappa B activity by trans-dominant p50 mutants. J Virol (1993) 1.14
Molecular effectors and modulators of hypericin-mediated cell death in bladder cancer cells. Oncogene (2007) 1.14
Anti-apoptotic activity of low levels of wild-type p53. EMBO J (1996) 1.13
Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB. Oncogene (2006) 1.13
Varicella-zoster virus latency in the adult rat is a useful model for human latent infection. Neurology (1995) 1.13
NF kappa B and interferon regulatory factor 1 physically interact and synergistically induce major histocompatibility class I gene expression. J Interferon Cytokine Res (1995) 1.12
Singlet oxygen-induced mutations in M13 lacZ phage DNA. EMBO J (1987) 1.12
High level of MT-MMP expression is associated with invasiveness of cervical cancer cells. Int J Cancer (1996) 1.11
Perceived need for dental care among persons living with acquired immunodeficiency syndrome. Med Care (1991) 1.11
Muscle-specific expression of the acetylcholine receptor alpha-subunit gene requires both positive and negative interactions between myogenic factors, Sp1 and GBF factors. EMBO J (1993) 1.10
Influence of innervation of myogenic factors and acetylcholine receptor alpha-subunit mRNAs. Neuroreport (1991) 1.08
Mutagenesis of the lac promoter region in M13 mp10 phage DNA by 4'-hydroxymethyl-4,5',8-trimethylpsoralen. Proc Natl Acad Sci U S A (1985) 1.07
Varicella-zoster virus open reading frame 4 encodes an immediate-early protein with posttranscriptional regulatory properties. J Virol (1997) 1.07
Mechanisms of persistent NF-kappa B activity in the bronchi of an animal model of asthma. J Immunol (2000) 1.06
Regulation of interleukin-6 gene expression by pro-inflammatory cytokines in a colon cancer cell line. Biochem J (2000) 1.05
Comparative immunohistochemical study of herpes simplex and varicella-zoster infections. Virchows Arch A Pathol Anat Histopathol (1993) 1.05
Multiple redox regulation in NF-kappaB transcription factor activation. Biol Chem (1997) 1.04
UVA-induced lipid peroxidation in cultured human fibroblasts. Biochim Biophys Acta (1991) 1.03
Distinct signal transduction pathways mediate nuclear factor-kappaB induction by IL-1beta in epithelial and lymphoid cells. J Immunol (1997) 1.03
CBP and histone deacetylase inhibition enhance the transactivation potential of the HOXB7 homeodomain-containing protein. Oncogene (1999) 1.03
Varicella-zoster virus infection of adult rat sensory neurons in vitro. J Virol (1989) 1.02
Transcriptional mapping of the varicella-zoster virus regulatory genes encoding open reading frames 4 and 63. J Virol (1994) 1.02
Correlation between nuclear factor-kappaB activity in bronchial brushing samples and lung dysfunction in an animal model of asthma. Am J Respir Crit Care Med (2000) 1.02
Cell type-specific role for reactive oxygen species in nuclear factor-kappaB activation by interleukin-1. Biochem Pharmacol (2000) 1.01
Retinoic acid induction of major histocompatibility complex class I genes in NTera-2 embryonal carcinoma cells involves induction of NF-kappa B (p50-p65) and retinoic acid receptor beta-retinoid X receptor beta heterodimers. Mol Cell Biol (1993) 1.00
Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. Oncol Res (1998) 1.00
Nuclear factor-kappaB activation by the photochemotherapeutic agent verteporfin. Blood (2000) 0.99
Physicochemical properties and stability of anthralin in model systems and human skin. J Invest Dermatol (1983) 0.99
Community-based case management for persons with AIDS. Health Aff (Millwood) (1989) 0.99
The homeodomain-containing proteins: an update on their interacting partners. Biochem Pharmacol (1999) 0.99
The role of the low density lipoprotein receptor pathway in the delivery of lipophilic photosensitizers in the photodynamic therapy of tumours. J Photochem Photobiol B (1991) 0.99
Endoplasmic reticulum and Golgi apparatus are the preferential sites of Foscan localisation in cultured tumour cells. Br J Cancer (2003) 0.98
Stimulation of glutathione peroxidase activity decreases HIV type 1 activation after oxidative stress. AIDS Res Hum Retroviruses (1994) 0.98
Characterisation of membrane oligonucleotide-binding proteins and oligonucleotide uptake in keratinocytes. Nucleic Acids Res (1999) 0.98
Importance of post-transcriptional regulation of chemokine genes by oxidative stress. Biochem J (2001) 0.98
Mechanism of colon cancer cell apoptosis mediated by pyropheophorbide-a methylester photosensitization. Oncogene (2001) 0.98
Activation of human immunodeficiency virus type 1 by oxidative stress. AIDS Res Hum Retroviruses (1990) 0.97
Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional. Oncogene (2011) 0.97
Purification of circular DNA using benzoylated naphthoylated DEAE-cellulose. DNA (1985) 0.97
Non-enzymatic triggering of the ceramide signalling cascade by solar UVA radiation. EMBO J (2000) 0.96
Mutational analysis of varicella-zoster virus major immediate-early protein IE62. Nucleic Acids Res (1995) 0.96
Stratum corneum is an effective barrier to TiO2 and ZnO nanoparticle percutaneous absorption. Skin Pharmacol Physiol (2009) 0.96
Breast cancer vaccines: a clinical reality or fairy tale? Ann Oncol (2005) 0.96
Inhibition of the NF-kappa B transcription factor increases Bax expression in cancer cell lines. Oncogene (2001) 0.96
Switch from p53 to MDM2 as differentiating human keratinocytes lose their proliferative potential and increase in cellular size. Oncogene (2000) 0.95